Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 with or without buparlisib for recurrent glioblastoma
NL-OMON45098Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capmatinib and buparlisib in glioblastoma (GBM) (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities, Progression-free survival rate and 1 more. Started Apr 2014; status: active, not recruiting.
02
Drugs
capmatinibbuparlisib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON45098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45098.